Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder
NCT ID: NCT00329264
Last Updated: 2009-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
876 participants
INTERVENTIONAL
2006-04-30
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder
NCT00329446
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
NCT00389064
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
NCT00322595
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
NCT00326144
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
NCT00320268
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine fumarate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be able to understand and comply with the requirements of the study.
* Able to understand and provide written informed consent
Exclusion Criteria
* Current or past diagnosis of stroke or transient ischemic attack (TIA).
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Willie Earley, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Springdale, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
Encino, California, United States
Research Site
Newport Beach, California, United States
Research Site
Oceanside, California, United States
Research Site
Redlands, California, United States
Research Site
Santa Ana, California, United States
Research Site
Denver, Colorado, United States
Research Site
Norwich, Connecticut, United States
Research Site
Washington D.C., District of Columbia, United States
Research Site
Fort Walton Beach, Florida, United States
Research Site
Gainsville, Florida, United States
Research Site
Hialeah, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Winter Park, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Smyrna, Georgia, United States
Research Site
Eagle, Idaho, United States
Research Site
Chicago, Illinois, United States
Research Site
Oak Brook, Illinois, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Topeka, Kansas, United States
Research Site
New Orleans, Louisiana, United States
Research SIte
Fall River, Massachusetts, United States
Research Site
Farmington Hills, Michigan, United States
Research Site
Ridgeland, Mississippi, United States
Research Site
St Louis, Missouri, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Cherry Hill, New Jersey, United States
Research Site
Clementon, New Jersey, United States
Research Site
Brooklyn, New York, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
Research Site
Staten Island, New York, United States
Research Site
Charlotte, North Carolina, United States
Research Site
Durham, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Toledo, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Tulsa, Oklahoma, United States
Research Site
Portland, Oregon, United States
Research Site
Allentown, Pennsylvania, United States
Research Site
Norristown, Pennsylvania, United States
Research Site
Lincoln, Rhode Island, United States
Research Site
Memphis, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Friendswood, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Woodstock, Vermont, United States
Research Site
Herndon, Virginia, United States
Research Site
Midlothian, Virginia, United States
Research Site
Bellevue, Washington, United States
Research Site
Seattle, Washington, United States
Research Site
Charleston, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Montgomery SA, Locklear JC, Svedsater H, Eriksson H. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder. Int Clin Psychopharmacol. 2014 Sep;29(5):252-62. doi: 10.1097/YIC.0000000000000026.
Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011 Dec;26(8):614-28. doi: 10.1002/hup.1256. Epub 2011 Dec 6.
Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011 Aug;31(4):418-28. doi: 10.1097/JCP.0b013e318224864d.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Titanium
Identifier Type: -
Identifier Source: secondary_id
D1448C00009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.